跳至主要内容
临床试验/NCT03001921
NCT03001921招募中不适用

Wise Practice of Chinese Hemodialysis (WISHES)

Sun Yat-sen University2 个研究点 分布在 1 个国家目标入组 30,000 人开始时间: 2013年12月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
30,000
试验地点
2
主要终点
Patient survival of HD patients

研究概览

简要总结

The investigators are registering all HD patients at recruited hospitals and developing a HD database in China. Patients will be follow-up every 3 months, and both baseline and follow-up information will be entered into the registration system. The patient survival, technical survival, patency rate of access, quality of life and residual renal function for HD patients will be compared using the HD database.

详细描述

The investigators are registering all end stage renal disease (ESRD) patients receiving hemodialysis (HD) treatment, and developing a HD database in China. Patients' demographic characteristics (including age, gender, height, weight, BMI, smoking, drinking, and education), clinical characteristics (including systolic blood pressure, diastolic blood pressure, primary cause of ESRD, and lab measurements of serum, urine, and access patency), complications, drug information and scores of quality of life at the baseline will be collected. Patients will be follow-up every 3 month, the demographic and clinical characteristics, complications and drug information of patients will be collected at each visit. The investigators also record the outcome at each visit, such as mortality (including all-cause mortality and cardiovascular disease mortality), technical survival, kidney transplantation, transfer to peritoneal dialysis, hospitalization, access failure,etc. The patient survival, technical survival, patency rate of access, quality of life and residual renal function for HD patients will be compared using the HD database.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • End stage renal disease patients receiving hemodialysis treatment.

排除标准

  • 未提供

研究组 & 干预措施

Hemodialysis patients

End stage renal disease patients receiving hemodialysis treatment

干预措施: No intervention (Other)

结局指标

主要结局

Patient survival of HD patients

时间窗: 10 years

次要结局

  • Patency rate of access for HD patients(10 years)
  • Quality of life evaluated using SF36 scale for HD patients(10 years)

研究者

发起方
Sun Yat-sen University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Xue Qing Yu

Professor

Sun Yat-sen University

研究点 (2)

Loading locations...

相似试验